Canada Markets closed

Xtant Medical Holdings, Inc. (XTNT)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.5702-0.0061 (-1.06%)
At close: 03:57PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.5763
Open0.5961
Bid0.5601 x 900
Ask0.5900 x 1800
Day's Range0.5611 - 0.5961
52 Week Range0.5300 - 6.5800
Volume48,114
Avg. Volume101,072
Market Cap49.491M
Beta (5Y Monthly)1.46
PE Ratio (TTM)N/A
EPS (TTM)-0.0400
Earnings DateFeb. 22, 2022 - Feb. 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Xtant Medical to Present at the H.C. Wainwright BioConnect Virtual Conference

    BELGRADE, Mont., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that Sean Browne, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Virtual Conference taking place January 10-13, 2022. A pre-recorded presentation will be available on the Investors section of the Company’s website at www.xtantmedical.com, beginning on

  • GlobeNewswire

    Xtant Medical Appoints Scott Neils Interim Chief Financial Officer

    BELGRADE, Mont., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the appointment of Scott Neils as Interim Chief Financial Officer succeeding Greg Jensen, the Company’s current Vice President, Finance and Chief Financial Officer, effective January 3, 2022. “We are excited to announce this well deserved promotion for Scott. His demonstrated

  • GlobeNewswire

    Xtant Medical Announces Third Quarter 2021 Financial Results

    BELGRADE, Mont., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and operating results for the third quarter ended September 30, 2021. Third Quarter 2021 Financial Highlights: Revenue for the third quarter of 2021 totaled $13.8 million, compared to $14.0 million for the prior-year periodLoss from operations totaled $1.4 million co